O’Melveny advised Vivo Capital as the leader of an investment syndicate in the investment syndicate’s definitive agreement to acquire Canadian medical device maker Angiotech Pharmaceuticals. Vivo…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
